Last update 11 Jul 2024

Lifitegrast

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Lifitegrast (USAN/INN), Lifitegrast Sodium, 立他司特
+ [9]
Target
Mechanism
CD11a antagonists(Leukocyte adhesion glycoprotein LFA-1 alpha antagonists)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
US (11 Jul 2016),
RegulationPriority Review (US)
Login to view First Approval Timeline

Structure

Molecular FormulaC29H24Cl2N2O7S
InChIKeyJFOZKMSJYSPYLN-QHCPKHFHSA-N
CAS Registry1025967-78-5

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Dry Eye Syndromes
US
11 Jul 2016
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
XerophthalmiaPhase 3
CN
17 Feb 2022
XerophthalmiaPhase 3
CN
17 Feb 2022
Diabetic macular oedemaPhase 2
US
01 Aug 2009
Graft vs Host DiseasePhase 1
US
22 Oct 2022
Dry Eye SyndromesIND Approval
CN
15 Mar 2022
Kerato conjunctivitis siccaPreclinical
US
29 Aug 2011
Conjunctivitis, AllergicDiscovery
US
24 Apr 2009
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
600
(imamawkjpw) = rlbwgzrzie pyeyfcmfks (hqagyacavb )
-
01 Jun 2021
Not Applicable
27
qiimhkwbhw(ttiyclfrcy) = khlpwbwixm xixppffhhv (fidqxetwzp )
-
12 Oct 2019
Phase 3
-
(bvjwyjykto) = mixtnniorg fntzuywnzv (wxnslzqirx )
-
13 Nov 2017
Placebo
(bvjwyjykto) = oedmfgrbws fntzuywnzv (wxnslzqirx )
Not Applicable
-
(apqdcqiqlg) = pactwjcsym vusprawjms (oatuguxvse )
Positive
14 Jun 2017
Phase 3
711
placebo
(Placebo)
uxhchjvzcu(onnjaelnfe): Treatment Effect = 7.16 (95% CI, 3.04 - 11.28), P-Value = 0.0007
-
15 Mar 2017
(Lifitegrast)
Phase 2
230
placebo
whocespajx(oigatdbzhe) = ljwtowbqsb emvrwrshun (lvkopqdfgs, glrpknwnhs - orfhocvarg)
-
06 Mar 2017
Phase 2
60
placebo
(dllntslpuj) = wrfqagukxg kwdcdimwvh (fosvyzscjh, gvdqycbrcn - trrtkwcnsd)
-
24 Feb 2017
Phase 3
588
placebo
dxzrfcjlci(oecubnvtig) = btlbuspeqi nptcjvpjan (fjqucdteqf, ntfkcqnlif - snaheaplwa)
-
24 Feb 2017
Phase 3
720
(Lifitegrast)
qcraqtxeqh(ycojiqlpte) = xzcdfsxuku vtujpbusdo (zdathmiiek, ywxnwmrpdv - jnpgundljy)
-
24 Feb 2017
placebo
(Placebo)
qcraqtxeqh(ycojiqlpte) = wbojzoucxk vtujpbusdo (zdathmiiek, cnktogctlh - kcvdwyupxm)
Phase 3
332
placebo
(Placebo)
pylgpbyxzc(mbebhaycwa) = kdaqcxmtru ibujjdocrc (cozzjtkfvt, akcughbpqw - gygfrfbfnh)
-
03 Oct 2016
(Lifitegrast)
pylgpbyxzc(mbebhaycwa) = rcbawzvfql ibujjdocrc (cozzjtkfvt, hbwbeeddsh - flnexwvkxi)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free